Work

FDA approval: Ryoncil (from Catapult's regulatory round-up for December 2024)

Year: 2025

Type: other

Abstract: FDA has approved Ryoncil (remestemcel-L-rknd), an allogeneic (donor) bone marrow-derived mesenchymal stromal cell (MSC) therapy indicated for the treatment of steroid-refractory acute graft-versus-host disease (SR-aGVHD) in pediatric patients 2 months of age and older. Steroid-refractory acute graft-versus-host disease is a serious and life-threatening condition that can occur as a complication of allogeneic hematopoietic (blood) stem cell transplantation (allo-HSCT). MSCs are a type of cell...

Source: Industrias Culturais (Universidade de Coimbra)

DOI: 10.58079/13axz

Author: Adelage

Language: English

Topic: Hematopoietic Stem Cell Transplantation

Subfield: Hematology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: green

OpenAlex ID: W6917650800

Cites:

Cited by:

Related to: